Amarin announces patent allowance related to combination of Vascepa, Statin Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol.
Subscribe for More Information
